**Journal of Health, Wellness and Community Research**
**ISSN: 3007, 0570**

OPEN ACCESS

**JHWCR**

**Type:** Narrative Review
**Published:** 13 October 2025
**Volume:** III, **Issue:** XIV
**DOI: https://doi.org/10.61919/m3tf9t39**

**Correspondence**
✉ Saleh Shah, salehshah83@gmail.com

**Received** 24, 08, 25 **Accepted** 02, 10, 2025

**Authors' Contributions**
Concept: RU; Design: MNB; Data Extraction: RU; Analysis: MNB; Drafting: SS.



**Declarations**
This study is supported by the Offices of Research Innovation and Commercialization (ORICS) by Khyber Medical University, (DIR/ORIC/Ref/25/00126).
The authors declare no conflict of interest. The study received ethical approval. All participants provided informed consent.

**"Click to Cite"**

# The Role of Imaging in Diagnosing Neurodegenerative Diseases: A Review of Current Techniques and Applications

**Rizwan Ullah[1,2], Muhammad Naveed Babur[1], Saleh Shah[1]**

1 Faculty of Allied Health Sciences, Superior University, Lahore, Pakistan
2 Institute of Paramedical Sciences, Khyber Medical University, Peshawar, Pakistan

## ABSTRACT

***Background:*** *Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) are major global health challenges characterized by progressive neuronal loss. Their early diagnosis remains difficult due to overlapping clinical features and the absence of definitive biochemical markers in the prodromal phase. Imaging techniques have transformed diagnostic neurology by providing non-invasive visualization of structural, functional, and molecular changes in the brain, thereby complementing clinical and biochemical assessments.* ***Objective:*** *This review aims to synthesize current evidence on the role of neuroimaging modalities in diagnosing neurodegenerative diseases, emphasizing their diagnostic value, emerging biomarkers, and potential for integration with biochemical and genetic data.* ***Methods****: A narrative review approach was adopted. Peer-reviewed studies published between 2010 and 2024 were identified through PubMed, Scopus, and Google Scholar using the keywords neurodegenerative diseases, MRI, PET, SPECT, biomarkers, and diagnostic imaging. Studies focusing on imaging-based diagnosis, disease differentiation, and biomarker validation in AD, PD, FTD, and ALS were included. Findings were synthesized thematically to describe diagnostic principles, clinical applications, and comparative strengths of each modality.* ***Results:*** *Magnetic resonance imaging (MRI) remains the cornerstone of structural assessment, identifying hallmark patterns such as hippocampal atrophy in AD and midbrain degeneration in PD. Functional imaging modalities—functional MRI (fMRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT)—enable detection of altered cerebral activity, hypometabolism, and perfusion abnormalities before overt atrophy occurs. Emerging techniques such as diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI), and hybrid PET/MRI systems enhance early detection by providing microstructural and molecular insights. Quantitative imaging biomarkers, including hippocampal volume, dopamine transporter activity, and cortical metabolic indices, demonstrate high diagnostic accuracy and facilitate longitudinal disease monitoring. Integrating imaging with CSF and genetic biomarkers further improves diagnostic specificity and enables precision stratification.* ***Conclusion:*** *Imaging serves as a cornerstone in the early and differential diagnosis of neurodegenerative diseases, bridging the gap between molecular pathology and clinical presentation. Despite challenges of cost, accessibility, and standardization, advancements in multimodal imaging, artificial intelligence, and quantitative biomarker analysis are transforming diagnostic neurology into a precision-based discipline. Continued technological integration promises earlier detection, individualized disease profiling, and optimized therapeutic interventions.*

***Keywords***
*Neurodegenerative Diseases; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Single-Photon Emission Computed Tomography (SPECT)*

## INTRODUCTION

Neurodegenerative diseases represent a major and escalating global health challenge, particularly as life expectancy continues to rise. The World Health Organization estimates that over 55 million individuals are living with dementia worldwide, a number projected to exceed 150 million by 2050, with Alzheimer's disease (AD) accounting for nearly two-thirds of all cases (1). Parkinson's disease (PD), the second most prevalent neurodegenerative disorder, affects approximately 10 million people globally, and its incidence is expected to double in the next two decades (2). Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), though less common, contribute substantially to morbidity and socioeconomic burden due to their early onset and rapid progression (3). Collectively, these conditions result in progressive cognitive, motor, and behavioral decline, imposing profound personal and public health consequences.

At the cellular level, neurodegeneration arises from converging pathogenic mechanisms, including abnormal protein aggregation, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation (4,5). In AD, the accumulation of β-amyloid plaques and hyperphosphorylated tau tangles leads to synaptic failure and neuronal death, particularly in the hippocampus and association cortices. PD is characterized by dopaminergic neuronal loss in the substantia nigra and the aggregation of α-synuclein into Lewy bodies (6). In FTD, abnormal accumulation of tau or TDP-43

proteins contributes to selective atrophy of the frontal and temporal lobes, while ALS involves progressive degeneration of upper and lower motor neurons associated with TDP-43 or FUS proteinopathy (7). These diverse yet overlapping mechanisms underscore the complexity of diagnosis, as different disorders often share molecular and clinical features.

Traditional diagnostic approaches based on clinical examination and neuropsychological assessment remain essential but are limited in sensitivity and specificity, particularly during the prodromal or early symptomatic phases (8). Many patients are diagnosed only after irreversible neuronal damage has occurred, leading to missed therapeutic windows. Biomarkers obtained from cerebrospinal fluid (CSF) and blood, such as β-amyloid, tau, and neurofilament light chain (NfL), have improved diagnostic accuracy but remain invasive, expensive, and influenced by pre-analytical variability (9). Consequently, there is a pressing need for non-invasive, reproducible, and quantifiable biomarkers that can detect disease-specific neurobiological changes before clinical manifestation—an area where imaging plays a transformative role.

Over the past four decades, neuroimaging has evolved from simple structural visualization to sophisticated molecular and functional assessment. Computed tomography (CT), introduced in the 1970s, provided the first opportunity to detect cortical atrophy and exclude alternative causes such as hemorrhage or tumor but lacked sensitivity to early neurodegenerative alterations (10). Magnetic resonance imaging (MRI) revolutionized brain imaging in the 1980s with superior soft tissue contrast and the ability to detect subtle regional volume loss. In the 1990s, the advent of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) enabled visualization of metabolic and perfusion changes preceding structural atrophy (11). The 2000s saw the emergence of diffusion tensor imaging (DTI) and susceptibility-weighted imaging (SWI), expanding the capacity to evaluate microstructural integrity and iron accumulation. In the last decade, advances in artificial intelligence (AI), machine learning, and hybrid PET/MRI systems have enabled multimodal integration, automated segmentation, and predictive modeling for early and differential diagnosis (12).

The rapid evolution of neuroimaging modalities reflects a paradigm shift from symptomatic diagnosis to mechanism-based, biomarker-driven precision medicine. This review synthesizes current evidence on the role of imaging in diagnosing major neurodegenerative diseases, emphasizing its utility in early detection, differential diagnosis, and disease monitoring. It also explores imaging biomarkers and their translational potential in clinical and research settings, highlighting limitations, challenges, and future directions.

## DIAGNOSTIC CHALLENGES IN NEURODEGENERATIVE DISEASES

Accurate diagnosis of neurodegenerative diseases remains challenging due to the significant overlap in their clinical presentations and underlying pathology. Early symptoms such as mild memory deficits, mood changes, or motor slowness are often nonspecific and can be mistaken for psychiatric, vascular, or metabolic conditions (13). The heterogeneity in disease progression and individual variability in symptom expression further complicate diagnosis, particularly in mixed or atypical cases. Studies have reported misdiagnosis rates of up to 30% between AD and FTD, largely due to overlapping cognitive and behavioral profiles (14). Similarly, early PD can be confused with essential tremor or atypical parkinsonian syndromes, and FTD may mimic psychiatric disorders, delaying appropriate management (15).

Clinical and neuropsychological assessments, although valuable, rely heavily on subjective interpretation and may not detect subclinical neuropathology. Neuropsychological tests assess cognitive domains such as memory, executive function, and visuospatial ability, but they often fail to differentiate between disorders with similar cognitive deficits (16). As a result, clinical diagnosis alone lacks sufficient predictive accuracy, particularly in early or rapidly progressive cases.

To enhance diagnostic confidence, molecular biomarkers have been incorporated into diagnostic frameworks. CSF assays for β-amyloid (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) have demonstrated utility in distinguishing AD from other dementias, while NfL levels in CSF and plasma correlate with axonal damage across multiple neurodegenerative conditions (17). However, these biochemical measures are invasive, expensive, and susceptible to methodological inconsistencies between laboratories, limiting their universal adoption (18). Blood-based biomarkers are promising but still under validation, and they cannot yet replace imaging in providing anatomical localization or tracking spatial patterns of degeneration.

Given these constraints, neuroimaging has emerged as an indispensable adjunct to clinical and biochemical evaluation. Imaging not only supports early and differential diagnosis by visualizing disease-specific structural and functional alterations but also allows longitudinal monitoring of disease progression and response to therapy (19). The integration of imaging modalities such as MRI, PET, and SPECT with CSF and genetic biomarkers has led to multimodal diagnostic algorithms that enhance precision and reproducibility. This combined approach offers a more comprehensive understanding of disease mechanisms and represents the future direction of diagnostic neurology.

## IMAGING MODALITIES IN NEURODEGENERATIVE DISEASES

Advances in neuroimaging have revolutionized the diagnosis and monitoring of neurodegenerative diseases by allowing in vivo visualization of structural, functional, and molecular alterations that precede overt clinical symptoms. Each imaging modality offers unique insights into different aspects of neuropathology, ranging from gross structural atrophy to subtle metabolic or perfusion changes. Rather than functioning in isolation, these modalities are often complementary—when combined, they enhance diagnostic precision, enable differentiation between disease subtypes, and assist in evaluating therapeutic response.

**Computed Tomography (CT)** is among the earliest and most accessible neuroimaging modalities used in clinical neurology. It operates through X-ray–based cross-sectional imaging to assess cerebral structures. Although its utility in detecting early neurodegenerative changes is limited due to low soft tissue contrast, CT remains valuable for ruling out alternative causes of cognitive decline such as tumors, infarcts, hemorrhages, or hydrocephalus (11). In advanced Alzheimer's disease, it can demonstrate global cortical thinning and ventricular enlargement indicative of cerebral atrophy. Despite being cost-effective and rapid, the exposure to ionizing radiation and reduced sensitivity to subtle parenchymal changes restrict its application as a primary diagnostic tool for neurodegeneration (12,13).

**Magnetic Resonance Imaging (MRI)** represents the gold standard for structural brain imaging and provides detailed assessment of gray and white matter without radiation exposure. Utilizing magnetic fields and radiofrequency signals, MRI sequences such as T1-weighted, T2-weighted, FLAIR, and diffusion-weighted imaging (DWI) enable detection of region-specific atrophy, demyelination, and ischemic lesions (14). In Alzheimer's disease, volumetric MRI identifies hippocampal and entorhinal cortex atrophy, whereas in Parkinson's disease, it reveals midbrain and substantia nigra alterations associated with dopaminergic loss (15). MRI is also essential for evaluating frontotemporal cortical thinning in

FTD and periventricular white matter lesions in vascular dementia (16). Advanced techniques such as diffusion tensor imaging (DTI) assess microstructural integrity, while susceptibility-weighted imaging (SWI) detects abnormal iron accumulation in Parkinsonian syndromes (17). Although MRI provides high diagnostic accuracy and excellent soft-tissue contrast, it remains costly and less accessible in resource-limited settings, with contraindications in patients carrying metallic implants (18).

**Functional MRI (fMRI)** extends beyond structural assessment by evaluating neural activity through blood oxygen level–dependent (BOLD) contrast, which reflects regional changes in cerebral blood flow during task performance or resting-state conditions (19). It enables the mapping of functional connectivity and network integrity in real time. In Alzheimer's disease, fMRI has demonstrated reduced activation in the hippocampal–default mode network (DMN), correlating with cognitive impairment and memory deficits (20). In Parkinson's disease, it reveals disrupted connectivity within basal ganglia–thalamocortical circuits, while in mild cognitive impairment (MCI), it captures early functional disconnection before structural atrophy becomes apparent (21,22). Despite its potential, fMRI is primarily a research tool because of its high analytical complexity, sensitivity to motion artifacts, and limited reproducibility in routine clinical environments (23).

**Positron Emission Tomography (PET)** provides molecular-level insights by quantifying cerebral glucose metabolism and visualizing pathological protein accumulations. Using radiotracers such as fluorodeoxyglucose (18F-FDG), PET can detect hypometabolic patterns characteristic of specific dementias—parietotemporal deficits in Alzheimer's, frontal hypometabolism in FTD, and occipital hypometabolism in Lewy body dementia (24). Amyloid and tau PET tracers allow in vivo visualization of hallmark AD pathologies, while dopamine transporter PET using tracers like 18F-DOPA aids early diagnosis of Parkinson's disease and differentiation from atypical parkinsonian disorders (25,26). PET thus serves as a crucial modality for both early diagnosis and monitoring therapeutic response, though its use is limited by high cost, exposure to ionizing radiation, and dependence on cyclotron-generated tracers (27).

**Single Photon Emission Computed Tomography (SPECT)** offers a functionally similar but more accessible alternative to PET, using gamma-emitting isotopes such as technetium-99m (Tc-99m) to assess cerebral perfusion and receptor activity (28). Perfusion SPECT reveals characteristic hypoperfusion in the parietotemporal regions of Alzheimer's disease and striatal perfusion deficits in Parkinson's disease (29). Although SPECT has lower spatial resolution compared to PET, its broader availability and lower operational costs make it a valuable diagnostic adjunct in centers without PET infrastructure (30).

Emerging techniques such as **DTI** and **SWI** have expanded the diagnostic spectrum of MRI. DTI quantifies fractional anisotropy, reflecting white matter tract integrity, and has shown sensitivity to early microstructural changes in AD and ALS, even when volumetric MRI appears normal (15). SWI visualizes tissue magnetic susceptibility, allowing the detection of abnormal iron accumulation and microhemorrhages associated with Parkinsonian and vascular pathologies (21). **Hybrid PET/MRI** systems represent the latest frontier, integrating molecular and structural information simultaneously to achieve improved diagnostic accuracy and reduced scan time (22). Collectively, these modalities reflect a shift toward multimodal, quantitative, and biologically informed imaging paradigms that underpin precision diagnostics in neurodegenerative disorders.

***Table 1. Imaging Modalities in Neurodegenerative Diseases***

| Modality | Principle | Primary Diagnostic Use | Key Findings / Applications | Advantages | Limitations | Representative References |
|---|---|---|---|---|---|---|
| **CT** | X-ray–based cross-sectional imaging | Exclude stroke, tumor; detect gross atrophy | Cortical thinning, ventricular enlargement, infarcts | Rapid, inexpensive, widely available | Poor soft-tissue contrast; limited sensitivity to early changes; radiation exposure | (11–13) |
| **MRI** | Magnetic field & radiofrequency imaging | Structural brain mapping | Hippocampal atrophy (AD), midbrain changes (PD), cortical thinning (FTD) | High spatial resolution; no radiation | Expensive; contraindicated with metal implants; limited availability | (14–18) |
| **fMRI** | BOLD contrast detecting neural activity | Functional and network analysis | Reduced DMN connectivity (AD), altered motor circuits (PD) | Non-invasive, functional mapping | Complex post-processing; motion sensitivity; not routine clinically | (19–23) |
| **PET** | Radiotracer-based metabolic and pathology imaging | Amyloid, tau, dopaminergic imaging | Parietotemporal hypometabolism (AD), plaque/tau detection, presynaptic dopaminergic loss | Detects molecular abnormalities before structural changes | High cost; radiation; limited tracer access | (24–27) |
| **SPECT** | Gamma tracer perfusion imaging | Cerebral blood flow and receptor mapping | Parietal hypoperfusion (AD), striatal loss (PD) | Cost-effective; wide availability | Lower resolution than PET/MRI; radiation exposure | (28–30) |
| **DTI / SWI** | MRI derivatives for microstructure and iron mapping | Early microstructural or mineral deposition detection | White matter disruption (AD, ALS); iron accumulation (PD) | Sensitive to subtle pathology; quantitative | Largely research-based; requires advanced analysis | (15,21,22) |

## IMAGING BIOMARKERS AND QUANTITATIVE PARAMETERS

Imaging biomarkers are quantifiable imaging-derived indicators that objectively reflect structural, functional, or molecular aspects of neurobiological processes. They serve as measurable correlates of disease presence, severity, and progression, enabling clinicians and researchers to transition from descriptive imaging to data-driven diagnosis and prognostication. In the context of neurodegenerative diseases, imaging biomarkers are broadly classified into three categories: **structural biomarkers**, which identify anatomical or volumetric changes; **functional biomarkers**, which evaluate cerebral activity, perfusion, or metabolism; and **molecular biomarkers**, which detect disease-specific protein accumulations or neurotransmitter alterations (31). Together, these imaging markers provide multidimensional insight into disease pathology and offer a foundation for precision neurology.

**Structural imaging biomarkers**, derived primarily from MRI, reveal the anatomical signatures of neurodegeneration. Volumetric MRI, for example, quantifies hippocampal atrophy in Alzheimer's disease—a hallmark finding that strongly correlates with cognitive decline and disease stage (9). Similarly, midbrain and substantia nigra atrophy patterns on MRI are indicative of Parkinson's disease, while frontotemporal cortical thinning characterizes frontotemporal dementia (16). Diffusion tensor imaging (DTI) adds quantitative value by measuring white matter tract integrity, allowing early detection of microstructural degeneration in conditions like amyotrophic lateral sclerosis (ALS) even before clinical symptoms become pronounced (31). These quantitative measures enable objective tracking of disease evolution, facilitating longitudinal assessments in both clinical trials and practice.

**Functional and metabolic biomarkers**, obtained through modalities such as PET, SPECT, and fMRI, visualize cerebral metabolism, perfusion, and network connectivity. Fluorodeoxyglucose (FDG)-PET identifies hypometabolic regions corresponding to neuronal dysfunction—parietotemporal deficits in Alzheimer's, frontal hypometabolism in FTD, and occipital changes in Lewy body dementia (13,14). Dopamine transporter imaging with SPECT or PET provides a functional biomarker for dopaminergic neuron integrity, differentiating idiopathic Parkinson's disease from atypical parkinsonian syndromes (25,26,32). Functional MRI, through blood oxygen level–dependent (BOLD) signals, complements these findings by mapping network-level connectivity alterations, which precede structural degeneration. Such biomarkers allow clinicians to distinguish between overlapping syndromes and refine diagnosis with greater confidence.

**Molecular imaging biomarkers** extend the diagnostic paradigm by directly targeting disease-specific proteins or receptor systems. Amyloid and tau PET tracers have transformed Alzheimer's diagnostics by enabling in vivo visualization of hallmark pathologies previously confirmed only through postmortem examination (24). In Parkinson's disease and related disorders, molecular tracers such as 18F-DOPA and 123I-FP-CIT (DaTscan) quantify presynaptic dopaminergic activity, while novel ligands targeting α-synuclein and neuroinflammatory markers are under development (32). These tools not only support early and differential diagnosis but also serve as pharmacodynamic markers in clinical trials, enabling objective monitoring of therapeutic effects.

Translationally, imaging biomarkers bridge the gap between research and clinical practice by standardizing quantification across cohorts and disease stages. Automated volumetric analysis, texture mapping, and machine-learning algorithms now permit high-throughput extraction of imaging features, advancing personalized prognostication and treatment planning. For instance, multimodal integration of MRI volumetrics, FDG-PET metabolism, and amyloid PET burden enhances diagnostic specificity for mixed or atypical dementias (30). Likewise, combining DTI-based connectivity metrics with fMRI-derived network analysis is improving early detection of ALS and FTD spectrum disorders. These quantitative imaging pipelines align with the broader trend toward biomarker-based disease classification, facilitating precision diagnostics and individualized intervention strategies.

***Table 2. Representative Imaging Biomarkers in Neurodegenerative Diseases***

| Disease | Imaging Biomarker | Modality | Diagnostic Role | Clinical Utility | Supporting References |
|---|---|---|---|---|---|
| **Alzheimer's Disease** | Hippocampal volume loss | MRI | Structural atrophy marker | Early detection, disease staging, prognostic assessment | (9,16) |
| **Parkinson's Disease** | Dopamine transporter loss | DAT-SPECT / PET | Functional biomarker of nigrostriatal degeneration | Differentiates PD from atypical parkinsonism; tracks dopaminergic decline | (25,26,32) |
| **Frontotemporal Dementia** | Frontal and temporal lobe hypometabolism | FDG-PET | Functional and metabolic marker | Distinguishes FTD from Alzheimer's; monitors disease progression | (13,14) |
| **Lewy Body Dementia** | Occipital hypometabolism | PET / SPECT | Diagnostic biomarker | Improves specificity in differentiating mixed dementias; complements clinical findings | (30,32) |
| **Amyotrophic Lateral Sclerosis (ALS)** | Corticospinal tract degeneration | DTI | Structural biomarker | Early-stage detection; longitudinal monitoring of motor pathway integrity | (31) |

# DISCUSSION

A comparative analysis of imaging modalities underscores that no single technique offers comprehensive diagnostic coverage across the neurodegenerative spectrum; rather, each modality provides a unique dimension of insight that becomes most powerful when interpreted synergistically. Structural imaging modalities such as MRI remain the cornerstone of diagnosis due to their high spatial resolution and reproducibility, allowing objective measurement of cortical and subcortical atrophy. However, they are limited in capturing early biochemical or synaptic dysfunction. Functional and molecular imaging—through PET, SPECT, and fMRI—fills this gap by revealing hypometabolism, perfusion deficits, and network-level disconnections that precede visible anatomical deterioration. For instance, PET demonstrates early parietotemporal hypometabolism in Alzheimer's disease, whereas MRI typically identifies atrophy only at a later stage. This complementarity justifies a multimodal diagnostic framework where structural, functional, and molecular signals converge to enhance sensitivity and specificity.

Integrating imaging biomarkers with biochemical and genetic data has further refined diagnostic precision and individualized prognostication. The convergence of imaging phenotypes—such as hippocampal atrophy or dopaminergic loss—with CSF biomarkers (Aβ42, tau, NfL) or pathogenic mutations (e.g., MAPT, SNCA, C9orf72) enables a multidimensional classification that distinguishes sporadic from hereditary forms and identifies preclinical disease stages. This integrative approach supports a biologically anchored diagnostic model, aligning with current trends in precision neurology and regulatory biomarker frameworks.

Nevertheless, imaging-based diagnosis presents inherent strengths and limitations. Its principal strength lies in its non-invasive, quantifiable visualization of in vivo pathology, providing dynamic information unattainable through postmortem or purely clinical means. Yet limitations include variability in acquisition protocols, lack of universal quantitative thresholds, and interpretive complexity, particularly in overlapping syndromes such as mixed Alzheimer's–vascular dementia. Inter-observer variability and dependence on advanced analytical infrastructure also challenge reproducibility. Moreover, while imaging biomarkers correlate strongly with pathology, they are not entirely specific—amyloid deposition, for example, may occur in cognitively normal older adults, complicating disease attribution.

Economic and ethical considerations further shape the global applicability of advanced imaging. PET and high-field MRI remain largely inaccessible in low- and middle-income countries due to cost, technical infrastructure, and scarcity of trained personnel. Ethical concerns include radiation exposure in PET/SPECT, over-reliance on imaging without sufficient clinical correlation, and data privacy issues arising from AI-assisted analysis. Thus, cost-effectiveness studies and equitable technology dissemination are essential to ensure that imaging advances translate into global clinical benefit.

The translational impact of multimodal and AI-driven diagnostic frameworks is already evident. Machine learning algorithms have demonstrated the ability to integrate MRI volumetrics, PET metabolic data, and clinical variables to predict conversion from mild cognitive impairment to Alzheimer's disease with accuracies exceeding 85%. Automated segmentation and radiomics approaches extract high-dimensional quantitative features—often imperceptible to the human eye—that correlate with molecular pathology and clinical outcomes. Such developments indicate a transformative trajectory where neuroimaging evolves from a descriptive tool to a predictive and decision-support system embedded within personalized medicine.

## CURRENT CHALLENGES AND FUTURE DIRECTIONS

Despite major advances, several challenges constrain the full integration of imaging into routine diagnostic workflows. Technical issues such as variability in acquisition protocols, scanner calibration, and reconstruction algorithms hinder standardization and reproducibility across centers. The absence of universally accepted quantitative thresholds for defining biomarker positivity limits comparability between studies and clinical populations. In research contexts, harmonizing imaging pipelines across multicenter trials remains a persistent challenge that impedes large-scale data pooling and meta-analysis.

Economic and infrastructural barriers further limit the widespread implementation of advanced imaging in resource-limited settings. The high cost of PET tracers, limited availability of cyclotrons, and maintenance requirements for MRI units impede accessibility. Development of cost-effective radiotracers, portable imaging units, and cloud-based data analysis platforms could mitigate these disparities. Similarly, initiatives toward open-source datasets and AI-based harmonization tools may reduce dependency on expensive proprietary systems, fostering democratization of imaging research. The next frontier lies in the development of next-generation tracers and quantitative imaging standards. Ongoing research focuses on novel PET ligands targeting α-synuclein, TDP-43, and neuroinflammatory markers—pathologies currently beyond the reach of conventional imaging. Parallel efforts in quantitative MRI seek to establish normative databases and cross-platform calibration metrics, enabling objective disease staging and treatment monitoring.




***Figure 1 Study Flowchart***

Longitudinal imaging studies are also pivotal for defining preclinical and prodromal disease stages. Tracking structural and metabolic changes over time provides invaluable insights into the temporal dynamics of neurodegeneration and aids in identifying individuals at high risk before symptom onset. Such approaches will be instrumental in evaluating disease-modifying therapies and preventive interventions.

Ultimately, the future of neurodiagnostics is moving toward **personalized imaging**—a paradigm where multimodal data, AI-assisted analytics, and genetic information converge to generate individualized risk profiles and treatment strategies. This evolution promises a shift from reactive symptom management to proactive, precision-based care, fundamentally transforming the landscape of neurodegenerative disease diagnosis and monitoring.

## CONCLUSION

Imaging has emerged as a cornerstone of modern neurodegenerative disease diagnostics, offering unparalleled insights into the structural, functional, and molecular underpinnings of neuronal degeneration. Through modalities such as MRI, PET, SPECT, and emerging hybrid systems, clinicians can now visualize disease processes that were once discernible only through postmortem examination. The integration of imaging biomarkers with biochemical and genetic indicators has improved diagnostic specificity, enabled earlier detection, and refined patient stratification for clinical trials.

While challenges persist—including cost, access disparities, and standardization gaps—the trajectory of neuroimaging is decisively forward-looking. The rise of multimodal imaging, machine learning, and quantitative biomarker analytics is ushering in an era of precision neurology, where diagnosis and prognosis are increasingly guided by objective, individualized data. Continued collaboration across disciplines will be essential to ensure that these technological advances translate into equitable and clinically meaningful outcomes.

In conclusion, the convergence of imaging innovation and translational research marks a pivotal evolution in neurodegenerative medicine. As imaging transitions from an adjunct diagnostic tool to a central pillar of disease management, it holds the promise of not only enhancing diagnostic accuracy but also transforming patient care through early intervention and personalized therapeutic guidance.

## REFERENCES

1. Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. *Cold Spring Harb Perspect Biol*. 2017;9(7):a028035.
2. Pimentel C, Batista-Nascimento L, Rodrigues-Pousada C, Menezes RA. Oxidative Stress in Alzheimer's and Parkinson's Diseases: Insights from the Yeast *Saccharomyces cerevisiae*. *Oxid Med Cell Longev*. 2012;2012:132146.

3. Reddy AP, Ravichandran J, Carkaci-Salli N. Neural Regeneration Therapies for Alzheimer's and Parkinson's Disease-Related Disorders. *Biochim Biophys Acta Mol Basis Dis*. 2020;1866(4):165506.
4. Krawczuk D, Kulczyńska-Przybik A, Mroczko B. Clinical Application of Blood Biomarkers in Neurodegenerative Diseases—Present and Future Perspectives. *Int J Mol Sci*. 2024;25(15):8259.
5. Ducharme S, Pijnenburg Y, Rohrer JD, Huey E, Finger E, Tatton N. Identifying and Diagnosing TDP-43 Neurodegenerative Diseases in Psychiatry. *Am J Geriatr Psychiatry*. 2024;32(1):98–113.
6. Pang SYY, Teo KC, Hsu JS, Chang RSK, Li M, Sham PC, et al. The Role of Gene Variants in the Pathogenesis of Neurodegenerative Disorders as Revealed by Next Generation Sequencing Studies: A Review. *Transl Neurodegener*. 2017;6(1):27.
7. Shusharina N, Yukhnenko D, Botman S, Sapunov V, Savinov V, Kamyshov G, et al. Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. *Diagnostics*. 2023;13(3):472.
8. Huang P, Zhang M. Magnetic Resonance Imaging Studies of Neurodegenerative Disease: From Methods to Translational Research. *Neurosci Bull*. 2023;39(1):99–112.
9. Del Sole A, Malaspina S, Magenta Biasina A. Magnetic Resonance Imaging and Positron Emission Tomography in the Diagnosis of Neurodegenerative Dementias. *Funct Neurol*. 2016;31(4):205–15.
10. Osborne T, Tang C, Sabarwal K, Prakash V. How to Interpret an Unenhanced CT Brain Scan: Part 2—Clinical Cases. *South Sudan Med J*. 2016;9(4):79–84.
11. Pasi M, Poggesi A, Pantoni L. The Use of CT in Dementia. *Int Psychogeriatr*. 2011;23(S2):S6–12.
12. Yen C, Lin CL, Chiang MC. Exploring the Frontiers of Neuroimaging: A Review of Recent Advances in Understanding Brain Functioning and Disorders. *Life (Basel)*. 2023;13(7):1552.
13. Wang LW, Cho KH, Chao PY, Kuo LW, Chiang CW, Chao CM, et al. White and Gray Matter Integrity Evaluated by MRI-DTI Can Serve as Noninvasive and Reliable Indicators of Structural and Functional Alterations in Chronic Neurotrauma. *Sci Rep*. 2024;14(1):57706. doi:10.1038/s41598-024-57706-7.
14. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial Temporal Lobe Atrophy on MRI Differentiates Alzheimer's Disease from Dementia with Lewy Bodies and Vascular Cognitive Impairment: A Prospective Study with Pathological Verification of Diagnosis. *Brain*. 2009;132(1):195–203. doi:10.1093/brain/awn298.
15. De Pietro S, Di Martino G, Caroprese M, Barillaro A, Cocozza S, Pacelli R, et al. The Role of MRI in Radiotherapy Planning: A Narrative Review "From Head to Toe." *Insights Imaging*. 2024;15(1):1–13.
16. Murali S, Ding H, Adedeji F, Qin C, Obungoloch J, Asllani I, et al. Bringing MRI to Low- and Middle-Income Countries: Directions, Challenges, and Potential Solutions. *NMR Biomed*. 2024;37(7):e4952.
17. Xiong F, Pan Y, Bai L. Research Applications of Functional Magnetic Resonance Imaging (fMRI) in Neuroscience. In: Lu J, Zhao G, editors. *PET/MR: Functional and Molecular Imaging of Neurological Diseases and Neurosciences.* Singapore: Springer Nature; 2023. p. 47–78. doi:10.1007/978-981-19-9902-4_3.
18. Perovnik M, Rus T, Schindlbeck KA, Eidelberg D. Functional Brain Networks in the Evaluation of Patients with Neurodegenerative Disorders. *Nat Rev Neurol*. 2023;19(2):73–90. doi:10.1038/s41582-022-00753-3.
19. Sarikaya I. PET Imaging in Neurology: Alzheimer's and Parkinson's Diseases. *Nucl Med Commun*. 2015;36(8):775–81.
20. Meyer PT, Frings L, Rücker G, Hellwig S. 18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. *J Nucl Med*. 2017;58(12):1888–98.
21. Price PM, Green MM. Positron Emission Tomography Imaging Approaches for External Beam Radiation Therapies: Current Status and Future Developments. *Br J Radiol*. 2011;84(Special Issue 1):S19–34. doi:10.1259/bjr/21263014.
22. Massari R, Mok GSP. New Trends in Single Photon Emission Computed Tomography (SPECT). *Front Med (Lausanne)*. 2023;10:1349877. doi:10.3389/fmed.2023.1349877.
23. Lee WW. Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography. *Nucl Med Mol Imaging*. 2019;53(3):172–81. doi:10.1007/s13139-019-00588-9.
24. Imokawa T, Yokoyama K, Takahashi K, Oyama J, Tsuchiya J, Sanjo N, et al. Brain Perfusion SPECT in Dementia: What Radiologists Should Know. *Jpn J Radiol*. 2024;42(11):1215–30. doi:10.1007/s11604-024-01612-5.
25. Mazón M, Costa JFV, Ten-Esteve A, Martí-Bonmatí L. Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases: The Example of Amyotrophic Lateral Sclerosis. *Front Neurosci*. 2018;12:824. doi:10.3389/fnins.2018.00824.
26. Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, et al. Imaging Biomarkers in Parkinson's Disease and Parkinsonian Syndromes: Current and Emerging Concepts. *Transl Neurodegener*. 2017;6(1):8.
27. Conte E. Facial Features as a New Biomarker for Early Identification of High-Risk Atherosclerosis: A Translational Approach. *Diagnostics*. 2024;14(5):1235.